5
Vardhaman Laboratories
524796 BSE
Vardhaman Laboratories
Healthcare BSE: 524796 Pharmaceuticals & Biotechnology
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company is almost debt free.
- Stock is trading at 0.11 times its book value
Weaknesses
2- Company has low interest coverage ratio.
- Company has a low return on equity of -1.79% over last 3 years.
Growth Rate
Revenue Growth
0%
Net Income Growth
-200% lower than
3Y
Quarterly Results
| Particulars | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0.03 | 0.02 | 0.01 | 0.03 | 0.02 | 0.02 | 0.04 | 0 | 0.01 | 0.02 | 0 | 0.01 | 0.01 |
| Operating Profit | -0.03 | -0.02 | -0.01 | -0.03 | -0.02 | -0.02 | -0.04 | 0 | -0.01 | -0.02 | 0 | -0.01 | -0.01 |
| Other Income | 0.01 | 0.01 | 0 | 0.01 | 0.01 | 0.04 | 0.01 | 0 | 0.01 | 0.01 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | -0.02 | -0.01 | -0.01 | -0.02 | -0.01 | 0.02 | -0.03 | 0 | 0 | -0.01 | 0 | -0.01 | -0.01 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — | — | 0% | — | 0% | 0% |
| Net Profit | -0.02 | -0.01 | -0.01 | -0.02 | -0.01 | 0.02 | -0.03 | 0 | 0 | -0.01 | 0 | -0.01 | -0.01 |
| EPS in Rs | -0.05 | -0.02 | -0.02 | -0.05 | -0.02 | 0.05 | -0.07 | 0 | 0 | -0.02 | 0 | -0.02 | -0.02 |
Profit & Loss
| Particulars | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.41 | 0.28 | 0.31 | 0.27 | 1.24 | 0.57 | 0 | 0 | 0 | 0 | -0.01 | -0.01 | 0 |
| Expenses | 0.57 | 0.58 | 0.54 | 0.44 | 1.23 | 0.57 | 0.02 | 0.04 | 0.06 | 0.08 | 0.07 | 0.07 | 0.04 |
| Operating Profit | -0.16 | -0.3 | -0.23 | -0.17 | 0.01 | 0 | -0.02 | -0.04 | -0.06 | -0.08 | -0.08 | -0.08 | -0.04 |
| OPM % | -39.02% | -107.14% | -74.19% | -62.96% | 0.81% | 0% | — | — | — | — | — | — | — |
| Other Income | 0.02 | 0.24 | 0.08 | 0.02 | 0.01 | 0.29 | -0.01 | 0.02 | 0.03 | 0.05 | 0.04 | 0.04 | 0.01 |
| Interest | 0.06 | 0.05 | 0.01 | 0 | 0.08 | 0 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0.11 | 0.11 | 0.1 | 0.08 | 0.08 | 0.02 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | -0.31 | -0.22 | -0.26 | -0.23 | -0.14 | 0.27 | -0.04 | -0.02 | -0.03 | -0.03 | -0.04 | -0.04 | -0.03 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 125% | 0% | 0% | 0% | 0% | 0% | — |
| Net Profit | -0.31 | -0.22 | -0.26 | -0.23 | -0.14 | 0.27 | -0.1 | -0.02 | -0.03 | -0.03 | -0.04 | -0.04 | -0.03 |
| EPS in Rs | -0.75 | -0.53 | -0.63 | -0.56 | -0.34 | 0.65 | -0.24 | -0.05 | -0.07 | -0.07 | -0.1 | -0.1 | -0.06 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.12 | 4.12 | 4.12 | 4.12 | 4.12 | 4.12 | 4.12 | 4.12 | 4.12 | 4.12 | 4.12 | 4.12 |
| Reserves | -1.04 | -1.26 | -1.52 | -2.01 | -2.12 | -1.87 | -1.97 | -1.99 | -2.02 | -2.05 | -2.09 | -2.13 |
| Borrowings | 0.74 | 0.34 | 0.21 | 0.24 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 0.16 | 0.03 | 0.19 | 0.25 | 1.12 | 0 | 0.02 | 0.01 | 0.01 | 0.03 | 0.02 | 0.04 |
| Total Liabilities | 3.98 | 3.23 | 3 | 2.6 | 3.12 | 2.25 | 2.17 | 2.14 | 2.11 | 2.1 | 2.05 | 2.03 |
| Fixed Assets | 2.29 | 2.19 | 2.09 | 1.63 | 1.59 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0.37 | 0.06 | 0.04 | 0.04 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1.32 | 0.98 | 0.87 | 0.93 | 1.53 | 2.25 | 2.17 | 2.14 | 2.11 | 2.1 | 2.05 | 2.03 |
| Total Assets | 3.98 | 3.23 | 3 | 2.6 | 3.12 | 2.25 | 2.17 | 2.14 | 2.11 | 2.1 | 2.05 | 2.03 |
Cash Flow
| Particulars | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -0.08 | 0.01 | 0.01 | -0.12 | 0.41 | -1.75 | -0.06 | 0.12 | 0.31 | 0 | -0.04 | 0.02 |
| Investing | -0.05 | 0.43 | 0.02 | 0 | 0.07 | 1.83 | 0 | 0 | 0 | 0 | 0 | 0 |
| Financing | 0.13 | -0.44 | -0.03 | 0.15 | -0.32 | -0.11 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Cash Flow | 0 | 0 | 0 | 0.03 | 0.16 | -0.03 | -0.06 | 0.12 | 0.31 | 0 | -0.04 | 0.02 |
| Free Cash Flow | -0.38 | 0 | 0.01 | -0.12 | 0.38 | -0.21 | -0.06 | 0.12 | 0.31 | 0 | -0.04 | 0.02 |
| CFO/OP | 50 | -3 | -4 | 71 | 4,100 | — | 50 | -300 | -517 | 0 | 50 | -25 |
Ratios
| Particulars | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 463 | 495 | 259 | 270 | 333 | 1,332 | — | — | — | — | -56,940 | -56,940 |
| Inventory Days | 813 | 1,460 | 920 | 1,460 | 65.05 | 0 | — | — | — | — | 0 | 0 |
| Days Payable | 265 | 73 | 102 | 279 | 351 | — | — | — | — | — | — | — |
| Cash Conversion Cycle | 1,010 | 1,882 | 1,077 | 1,451 | 47.13 | 1,332 | — | — | — | — | -56,940 | -56,940 |
| Working Capital Days | 1,024 | 1,238 | 918 | 1,014 | 97.14 | 1,332 | — | — | — | — | 56,940 | 57,305 |
| ROCE % | -6.44% | -7.98% | -8.32% | -8.91% | -2.76% | -0.94% | -0.45% | -0.93% | -1.42% | -1.44% | -1.95% | -1.99% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Vardhaman Laboratories insights
46 extracted metrics + investor summaries across FY07–FY18.
Documents
1
Outcome of Board Meeting
14 February 2026 - Board approved subscription up to Rs.10 Crore in 0.1% CCPS of MDN Edify Education; completion within 60 days. 14 February 2026 - Board approved subscription up to Rs.10 Crore in 0.1% CCPS of MDN Edify Education; completion within 60 days.
2
Acquisition
14 February 2026 - Board approved up to Rs10 Crore subscription to 0.1% CCPS of MDN Edify Education Pvt Ltd (Rs200/share). 14 February 2026 - Board approved up to Rs10 Crore subscription to 0.1% CCPS of MDN Edify Education Pvt Ltd (Rs200/share).
3
Price movement
10 February 2026 - Investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written … 10 February 2026 - Investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written …
4
Outcome of Board Meeting
20 January 2026 - Board meeting adjourned; investment agenda deferred; next meeting date to be notified (20 Jan 2026, 6:30–7:15 PM). 20 January 2026 - Board meeting adjourned; investment agenda deferred; next meeting date to be notified (20 Jan 2026, 6:30–7:15 PM).
5
Certificate under SEBI (Depositories and Participants) Regulations, 2018
17 January 2026 - RTA certificate: no dematerialisation requests during 01/10/2025–31/12/2025 (quarter ended 31 Dec 2025). 17 January 2026 - RTA certificate: no dematerialisation requests during 01/10/2025–31/12/2025 (quarter ended 31 Dec 2025).
Frequently Asked Questions about Vardhaman Laboratories
What does Vardhaman Laboratories Ltd do?
Vardhaman Laboratories is engaged in the business of Manufacturing of pharmaceutical products.
Where is Vardhaman Laboratories Ltd (524796) listed?
Vardhaman Laboratories Ltd trades under code 524796 on the BSE.
Which sector does Vardhaman Laboratories Ltd belong to?
Vardhaman Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
Company Information
Vardhaman Laboratories is engaged in the business of Manufacturing of pharmaceutical products.
Listed 2006-03-02
Face Value ₹ 10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524796.md for Vardhaman Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.